Have A Question?
Contact us
UK Ireland
T: 44 (0) 1707 37 22 11
T: 353 (0) 16 40 18 18

Roche delivers solid results in 2014 28 January 2015

Group sales up 5% at constant exchange rates1, 1% in Swiss francs

Pharmaceuticals Division sales up 4%, driven by oncology (HER2-positive breast cancer medicines, Avastin) and strong growth in immunology (Actemra, Xolair)

Diagnostics Division sales up 6%, driven by Professional Diagnostics and Molecular Diagnostics

Core earnings per share increased by 5% to 14.29 Swiss francs; up 7% excluding one-time double charge of the US Branded Prescription Drug fee2

Board proposes dividend increase of 3% to 8.00 Swiss francs, 28th consecutive year of dividend growth

Outlook for 2015: Sales expected to grow low-to mid-single digit, at constant exchange rates. Core earnings per share targeted to grow at constant exchange rates ahead of sales.

Roche expects to further increase its dividend in Swiss francs.